Anta Gkelou

The Future of Toxicity Testing Is Here — and It’s Non-Animal With the passage of the FDA Modernization Act 3.0 and the FDA-NIH roadmap to reduce animal use, New Approach Methodologies (NAMs) are rapidly becoming the standard for preclinical safety testing. At the recent FDA-NIH Workshop on July 7, the NIH announced it will no longer fund grant proposals solely based on animal testing—signaling a major shift toward ethical, efficient alternatives. Syngene’s NAM Portfolio Includes: 🔹 Computational Toxicity Prediction 🔹In silico immunogenicity assessment 🔹HeptToxTM for exposure-dependent hepatotoxicity 🔹Next Generation Risk Assessment (NGRA) 🔹Integrated Approaches to Testing and Assessment (IATA) 🔹OECD & ISO-compliant in vitro tests for: - Skin corrosion & irritation (OECD 431/439) - Eye irritation (OECD 492) - Skin absorption (OECD 428) - Skin sensitization (OECD 442) - Phototoxicity & cytotoxicity (OECD 432, ISO 10993-5) Whether you're in cosmetics, chemicals, or drug development, our experts can help you integrate NAMs into your testing programs—ensuring regulatory alignment and scientific confidence. Reach out to our team to explore how our in vitro and computational models can support your next study. https://lnkd.in/gCqrUPJU #NAM #NonAnimalTesting #InVitroModels #ComputationalToxicology #FDA #NIH #Toxicology #RegulatoryScience #SyngeneScience #PuttingScienceToWork

82

3 commentaires

"What fascinates me about #singlecell and #spatial is the ability to see not only heterogeneity across cell types, but heterogeneity within cell types." – Nigel Delaney, Vice President of Computational Biology, 10x Genomics We caught up with Nigel and asked him to give us the scoop on how single cell and spatial complement each other, and why this combination is a powerful tool for discovery. Bringing these approaches together—and integrating the rich, multimodal data from single cell assays into spatial frameworks—will unlock transformative insights into biological complexity. Unlock the full spectrum of biology with our Xenium platform, learn more here: https://bit.ly/4oyj4Ef

142

1 commentaire

#MPS2025 – Final Day! We're closing out the week as Vincent van Duinen presents one of our most advanced applications yet: An automated and multiplexed liver fibrosis screening assay, developed on a microfluidic liver model that mirrors the cellular composition and spatial organization of the hepatic lobule.  This work was part of Theme 3.6: Drug discovery for precision medicine —highlighting how organ-on-a-chip technology can support more predictive, human-relevant screening in fibrotic disease research. By integrating automated handling with a physiologically structured co-culture, this platform opens the door to higher-throughput and more informative liver fibrosis assays — bridging functional data and structure in a way that static models cannot. 📥 Want to explore some of the data?  Download the poster: https://lnkd.in/ehfzXDEC  Thank you to everyone who joined us this week at #MPS2025 — whether at a talk, at our booth, or in discussion. See you next year!  #OrganOnAChip #LiverFibrosis #Microfluidics #PrecisionMedicine #Toxicology  

56

𝗡𝗮𝗻𝗼𝗩𝗮𝘁𝗶𝗼𝗻 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗼𝗻 𝗕𝗶𝗼𝗧𝗲𝗰𝗵 𝗧𝗩 Two of our co-founders, Pieter Cullis and Jayesh Kulkarni, discuss the challenge of successfully using lipid nanoparticles (#LNPs) to deliver payloads beyond the liver—one of the key frontiers in drug delivery. A big thank you to BiotechTV for highlighting our work and perspective on this critical research focus, which has been at the heart of NanoVation Therapeutics since its inception. 🎥 𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝗵𝗲𝗿𝗲: https://lnkd.in/gbeSwZG9 #NanoVationTherapeutics #Biotech #LipidNanoparticles #DrugDelivery #Innovation #BioTechTV #NucleicAcids #GeneticMedicine

142

1 commentaire

#PortfolioNews | We're proud to share that our #portfolio company Neurona Therapeutics has dosed the first patient in its Phase 1/2 clinical trial of NRTX-1001 in drug-resistant bilateral mesial temporal lobe #epilepsy (MTLE). 💉 Bilateral trial milestone This is the first clinical evaluation of NRTX-1001 delivered to both temporal lobes. ✅ No surgical complications or therapy-related adverse events reported to date 💰 Backed by additional public investment Supported by a $14M grant from the California Institute for Regenerative Medicine (CIRM) 📊 Built on strong foundations The trial builds on encouraging results from Neurona’s unilateral MTLE study: • Up to 92% median seizure reduction • Preserved cognitive function in all treated patients 🔬 Enrollment completed in a new expansion cohort (8 patients) in the unilateral MTLE study 🎯 Toward regulatory submission Together with results from the previously announced Phase 3 EPIC study in unilateral MTLE, these data are intended to support a future Biologics License Application (BLA) for NRTX-1001. 👏 We’re proud to support Neurona as they advance targeted cell therapies for patients with severe forms of epilepsy. 🔗 Learn more: https://buff.ly/8sQelT7 #Biotech #CellTherapy #Epilepsy #Neuroscience #ClinicalTrials #Innovation #CNS #YsiosCapital #YsiosPortfolio

64

2 commentaires

🚀 SR-Tiget is proud to witness its research results making impactful strides in the #CancerImmunotherapy field We are excited to share news from Genenta Science (Nasdaq: GNTA) regarding the successful €20 million financing to expand their pipeline. It is rewarding to see that #Temferon – a hematopoietic stem cell-based #genetherapy drug originally developed by SR-Tiget scientists - is paving the way for important advancements in treating conditions like #glioblastoma multiforme.   💬 As #LuigiNaldini, co-funder of Genenta, explains: “We are continuing to demonstrate at pre-clinical and clinical levels Temferon’s ability to reprogram the tumor microenvironment, which in turn induces cell-mediated immune responses, as suggested by Genenta's ongoing glioblastoma multiforme trial and which will be under testing in the Company's metastatic Renal Cell Cancer trial.”   👉 Read more here https://lnkd.in/ecUuS9hU   #Innovation #Biotech 

37

In protein therapeutics, specificity is everything. But multi-specificity — the ability of a single molecule to engage multiple binding sites or targets simultaneously — opens entirely new therapeutic possibilities. At Affibody, we’ve engineered a platform that enables precise and customizable multi-specificity of our Affibody® molecules.  Why is this beneficial? 🔹 Enhanced efficacy – Multi-specific molecules can block signaling more completely or influence parallel pathways for a more robust therapeutic effect.  🔹 Reduced resistance – Targeting multiple epitopes or mechanisms simultaneously lowers the risk of treatment escape.  🔹 Improved specificity and safety – Dual targeting can improve selectivity for diseased tissue while minimizing effects on healthy cells, supporting a better safety profile.  🔹 Therapeutic streamlining – A single multi-specific molecule can replace the need for combination therapies, simplifying development, dosing, and patient experience. In short, multi-specificity gives us a powerful tool to design better, more efficient therapies.  Learn more about our molecular engineering approach:  https://lnkd.in/diPbtqpw    #ProteinEngineering #Biotech #Biologics 

27

1 commentaire

Excited to share that several of our Iambic Therapeutics colleagues will present at next week’s High Throughput Chemistry and Chemical Biology Gordon Research Conference, which is focused on generative AI for drug discovery. They will highlight the automation powering the integrated AI and high-throughput experimentation platform behind our clinical pipeline — as well as advances to NeuralPLexer, Iambic’s leading model for protein-ligand structure prediction. Talks and poster presentations by our scientists and machine learning innovators include: Joseph Dennis, Principal Scientist, Medicinal Chemistry Talk: Leveraging Automation in a High-Throughput Experimentation Platform to Fuel ML-Driven Drug Discovery Mia A. Rosenfeld, PhD, Machine Learning Scientist Talk: NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models James Garrafa-Luna, Associate Scientist II, High-Throughput Experimentation Poster: Empowering Iambic’s High-Throughput Experimentation Platform through Software and Reaction Optimization A shout-out also to Alexander Buitrago Santanilla, PhD., Iambic’s Associate Director, High-Throughput Experimentation, for his work as Vice-Chair of this year’s HTCCB event. Learn more about the conference here: https://lnkd.in/eXv3AsuD #AI #DrugDiscovery #HighThroughputChemistry #MachineLearning

106

2 commentaires

Step inside Cambridge's newest genomics lab! 🏢 The Functional Genomics Screening Laboratory (FGSL) at the Milner Therapeutics Institute is set to advance our understanding of health and disease 🧬 Scientists here are specialists in automation, screening and models, working with robotics to study human models of development and disease at scale 🖥️ As part of the UK Human Functional Genomics Initiative, the FGSL is helping the UK build one of the most advanced healthcare systems in the world 🏥 This lab is a joint venture between the Milner Therapeutics Institute, the Medical Research Council and AstraZeneca 🤝 #CambridgeUniversity #CambridgeResearch #Genomics

144

2 commentaires

How 𝗖𝗲𝗻𝘁𝗼𝗚𝗲𝗻𝗼𝗺𝗲® 𝗨𝗹𝘁𝗿𝗮-𝗙𝗮𝘀𝘁 is transforming genetic diagnostics with Eleni Perrakis, PhD – 𝗦𝗲𝗻𝗶𝗼𝗿 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 at CENTOGENE. In this short clip from our recent webinar, Eleni walks you through: 🔹 What makes CentoGenome® Ultra-Fast unique 🔹 The key advantages for clinical practice 🔹 A step-by-step look at how it works We are committed to making faster, more precise diagnoses accessible to patients around the world. 🌍💙 Learn more about our tests here: https://lnkd.in/dw5rtF52 #Genomics #RareDiseases #Innovation #CENTOGENE

62